Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis

Table 1 Clinical characteristics of SSc patients in the cutaneous immunohistochemical analysis

Clinical information	Healthy	dcSSc	lcSSc
Total number	30	50	10
Sex (female:male)	21:9 (70%:30%)	35:15 (70%:30%)	8:2 (80%:20%)
Race	Caucasian (100%)	Caucasian (100%)	Caucasian (100%)
Age (years)^a	46.7 ± 13.3	45.5 ± 11.9	61.2 ± 9.4
mRSS^a	-	19.1 ± 4.4	8.1 ± 1.9
Disease duration (years)^a	-	3.2 ± 2.2	7.7 ± 3.8
DMARD therapy	-	12 (24%)	1 (10%)
CRP elevation	-	18 (36%)	0 (0%)
Anti-Scl-70	-	15 (30%)	0 (0%)

Values are expressed as absolute number (%) unless otherwise indicated
Abbreviations: dcSSc diffuse cutaneous systemic sclerosis, lcSSc limited cutaneous systemic sclerosis, mRSS modified Rodnan skin score, DMARD disease-modifying anti-rheumatic drug, CRP C-reactive protein, Anti-Scl-70 anti-topoisomerase I antibodies
^aValues expressed as mean ± SEM

ISSN: 1478-6362